4 documents found, page 1 of 1
A multinational Delphi consensus to end the COVID-19 public health threat
COVID-19 Consensus Statement Panel; Lazarus, Jeffrey V.; Romero, Diana; Kopka, Christopher J.; Karim, Salim Abdool; Abu-Raddad, Laith J.Despite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic1,2. Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel of 386 academic, health, non-governmental organization, government and other experts in COVID-19 response from 112 countries and territories to recommend specific...
The EASL–Lancet Liver Commission: protecting the next generation of Europeans a...
Karlsen, Tom H.; Sheron, Nick; Zelber-Sagi, Shira; Carrieri, Patrizia; Dusheiko, Geoffrey; Bugianesi, Elisabetta; Pryke, Rachel; Hutchinson, Sharon J.Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the increasingly widespread unhealthy use of alcohol, the epidemic of obesity, and undiagnosed or untreated liver disease in migrant populations. Consequently, Europe is facing a looming syndemic, in which socioeconomic...
Innovative strategies for the elimination of viral hepatitis at a national leve...
Schröeder, Sophia E.; Pedrana, Alisa; Scott, Nick; Wilson, David; Kuschel, Christian; Aufegger, Lisa; Atun, Rifat; Baptista-Leite, RicardoViral hepatitis is a leading cause of morbidity and mortality worldwide, but has long been neglected by national and international policymakers. Recent modelling studies suggest that investing in the global elimination of viral hepatitis is feasible and cost-effective. In 2016, all 194 member states of the World Health Organization endorsed the goal to eliminate viral hepatitis as a public health threat by 2030...
Pathways to ensure universal and affordable access to hepatitis C treatment
Douglass, Caitlin H.; Pedrana, Alisa; Lazarus, Jeffrey V.; Hoen'T, Ellen F. M.; Hammad, Radi; Leite, Ricardo Baptista; Hill, Andrew; Hellard, MargaretDirect-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C treatment and prevention. The World Health Organization has called for the elimination of hepatitis C as a public health threat by 2030. However, the discrepancy in DAA prices across low-, middle- and high-income countries is considerable, ranging from less than US 100 to approximately US 40,000 per course, thus representing ...